Will BMS and Gilead divide hepatitis C treatment market?

BMS and Gilead have drawn a picture to divide the domestic hepatitis C treatment market.

According to the industry, the Ministry of Health and Welfare decided to register Sovaldi(generic name: sofosbuvir) and Harvoni(generic name: ledipasvir+sofosbuvir), Gilead’s hepatitis C treatments, for the national health insurance at the National Health Insurance Policy Deliberation Committee on the 18^t...